Navigation Links
Omeros Announces Proposed Public Offering of Common Stock
Date:6/26/2012

SEATTLE, June 26, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock in a registered underwritten public offering. Omeros also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover overallotments, if any.

Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to the clinical development of Omeros' two ongoing Phase 3 clinical development programs – OMS302 for use during intraocular lens replacement procedures and OMS103HP for use during arthroscopic partial meniscectomy surgery.  The net offering proceeds may also be used to fund research and development in Omeros' preclinical studies and clinical trials, capital expenditures, working capital and to otherwise advance Omeros' product candidates toward commercialization.

Cowen and Company, LLC and Deutsche Bank Securities Inc. are acting as the joint book-running managers for the offering.

Omeros intends to offer and sell these securities pursuant to its existing shelf registration statement (File No. 333-169856), which was filed with the Securities and Exchange Commission on October 8, 2010 and declared effective on October 18, 2010. A prospectus supplement describing the terms of the offering will be filed with the Securities and Exchange Commission and will form a part of the effective registration statement. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140), or Deutsche Bank Securities Inc., Attn: Prospectus Group, 60 Wall Street, New York, NY 10005-2836 or by telephone at: (800) 503-4611, or by email at: prospectus.CPDG@db.com. An electronic copy of the prospectus supplement and accompanying prospectus relating to the offering is available on the website of the Securities and Exchange Commission at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Omeros, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  The offering of Omeros common stock will be made only by means of the prospectus and related prospectus supplement meeting the requirements of Section 10 of the Securities Act of 1933.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system.

Forward-looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding Omeros' expectations regarding the underwritten public offering announced today. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2012. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros to Present at Jefferies 2012 Global Healthcare Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Deutsche Bank Securities Health Care Conference
4. Talyst Announces New Automated Medication Packager
5. Thermal Gradient Announces Manufacture of Next Generation DNA Testing Device
6. PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
7. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
8. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
9. Shire Announces that the US Food and Drug Administration has Responded to its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR
10. ERT Announces Stockholder Approval of Merger
11. Biodel Announces $18.5 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences Ltd. ... specializing in the development of cannabinoid-based drugs, today ... company overview at three upcoming scientific and investor ... LD Micro Invitational: ... Date:                     ...
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, ... innovative medical devices for pressure ulcer prevention, will ... American Association of Critical Care Nurses, National Teaching ... 22-25. The Leaf Patient Monitoring System ... for the hospital environment.  The system seamlessly tracks ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... East Los Angeles dentist, ... indicate about early life experiences. What happens to a woman during pregnancy can have ... birth can also take a toll on a baby’s long-term health. This study, which ...
(Date:6/26/2017)... , ... June 26, 2017 , ... Torrance dentist, Dr. ... can be one of the most noticeable aspects of a person’s appearance. A healthy, ... everyone is born with beautiful, balanced teeth, everyone can have the smile of their ...
(Date:6/26/2017)... ... June 26, 2017 , ... Dr. ... Medicine Specialists, in collaboration with the Fertility Center of California, is pleased to ... (percutaneous epidydimal sperm aspiration) and TESA (percutaneous testicular sperm extraction). These minimally invasive ...
(Date:6/26/2017)... , ... June 26, 2017 , ... ... to a recent review of government data released by the United Soybean Board. ... management practices, Maryland’s soybean farmers have increased their productivity on less land per ...
(Date:6/26/2017)... Tahoe, CA (PRWEB) , ... June 26, 2017 , ... ... 10,000 qualified mental health professionals in every state across the country to join its ... easy and rewarding way for therapists to reach a substantially greater number of people ...
Breaking Medicine News(10 mins):